DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMIZED CLINICAL TRIAL OF THE SAFETY AND EFFICACY OF BOTULINUM TOXIN TYPE A (BOTOX) IN BRUXISM

Trial Profile

DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMIZED CLINICAL TRIAL OF THE SAFETY AND EFFICACY OF BOTULINUM TOXIN TYPE A (BOTOX) IN BRUXISM

Completed
Phase of Trial: Phase IV

Latest Information Update: 12 Feb 2018

At a glance

  • Drugs Botulinum-Toxin-A (Primary)
  • Indications Sleep bruxism
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Feb 2018 New trial record
    • 17 Jan 2018 Primary endpoint efficacy as assessed by clinical global impressions (CGIs)) has been met, according to results published in the Neurology.
    • 17 Jan 2018 Results assessing safety and efficacy of onabotulinum toxin-A (BoNT-A) injections into the masseter and temporalis muscles in patients with symptomatic sleep bruxism, were published in the Neurology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top